Abstract��OBJECTIVE To evaluate the pharmacokinetics characteristics and safety of antipsytrotic ziprasidone mesylate with single dose intramuscularly injected in healthy volunteers. METHODS A total of 12 healthy Chinese volunteers(male 6 cases and female 6 cases) were received intramuscularly single dose of ziprasidone mesylate, the dosage was 10 mg.Blood samples were collected at different time after intramuscularly injection.The concentrations of ziprasidone in serum were determined by LC-MS/MS, and the pharmacokinetic parameters were calculated. RESULTS The concentration-time curves of ziprasidone fitted to two-compartment model.The pharmacokinetic parameters were stated as follows, ��max was (97.85�� 29.24) ng��mL-1;tmax was (0.56��0.30)h;MRT was (5.35��0.96) h; t1/2 was (4.29��0.88)h; AUC0��t was (405.6��98.68) ng��h��mL-1,AUC0���� was (413.3�� 100.69)ng��h��mL-1; CL was (25.50��6.10)L��h-1; Vd was (157.48��47.60)L; Kel was (0.168��0.035)h. There were no significant differences of the parameters between the male and female subjects. The common adverse events were somnolence, nausea and weakness with the severity of mild to moderate. CONCLUSION The pharmacokinetic parameters in 12 healthy volunteers after intramuscular injection of 10 mg ziprasidone mesylate are in line with that reported in the literature. This medicine has effect of sedation, so that it could be used to control the excited agitation.
����, ���컪, ���۷�, ���. ���μ���ע���ü���������ͪ���й�����־Ը���е�ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2017, 52(9): 767-771.
WANG Yun, GE Qing-hua, WANG Hui-fang, LI Hua-fang. Pharmacokinetics of Single Dose Intramuscularly Injected Ziprasidone Mesylate in Chinese Healthy Volunteers. Chinese Pharmaceutical Journal, 2017, 52(9): 767-771.
CALEY C F, COOPER C K. Ziprasidone: the fifth atypical antipsychotic[J]. Ann Pharmacother, 2002, 36(5):839-851.
[2]
WEI J. The progress of ziprasidone: proceedings of the ninth annual conference of morita therapeutics and the annual meeting of Tianjin Mental Health Association in 2012[C]. Tianjin:Tianjin Mental Health Association, 2002:1-5.
[3]
ZIMBROFF D L, ALLEN M H, BATTAGLIA J, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience[J]. CNS Spectr, 2005,10(9):1-15.
[4]
PREVAL H, KLOTZ S G, SOUTHARD R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study[J]. Gen Hosp Psychiatry, 2005,27(2):140-144.
[5]
DANIEL D G, POTKIN S G, REEVES K R, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial[J]. Psychopharmacology (Berl), 2001, 155(2):128-134.
[6]
PRESKORN S H. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone[J]. Clin Pharmacolinet, 2005, 44(11):1117-1133.
[7]
YANG J, YANG Z F, TIAN Y, et al. Determination of hydroxysafflor yellow A in human plasma by HPLC-UV[J]. PLA(��ž�ҩѧѧ��), 2009,25(1): 68-70.
[8]
WEN A, YANG J, JIA Y, et al. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of hydroxysafflor yellow A in human plasma: application to a pharmacokinetic study [J]. J Chromatogr B, Analyt Technol Biomed Life Sci, 2008,876(1):41-46.
[9]
GUNASEKARA N S,SPENCER C M,KEATING G M. Ziprasidone:a review of its use in schizopherenia and schizoaffective disorder[J]. Drugs, 2002,62(8):1217-1251.
[10]
BROOK S. Intramuscular ziprasidone:moving beyond the conventional in the treatment of acute agitation in schizophrenia[J].J Clin Psychiatry,2003,64(suppl):13-18.
2017, Vol. 52 
